Reviews found that women are more likely to develop “significantly” longer COVIDs

According to a new literature review, women are “significantly” more likely to develop long-term COVID and experience different symptoms than men, and of gender-specific studies to find a coordinated approach for prevention and treatment. Emphasizes the need. disease..

Studies published this week Current medical research and opinions, We found that women were 22% more likely than men to have long COVIDs defined as having symptoms that lasted more than 4 weeks after onset.

“Knowledge of the clinical manifestations of COVID-19, disease progression, and the underlying gender differences that underpin health outcomes includes both potential discriminatory treatment needs and sensitive and effective treatments. It is essential for the identification and rational design of public health interventions. Gender, “written the authors employed by Johnson & Johnson, who funded the study.

“Differences in immune system function between women and men can be an important factor in gender differences in Long COVID syndrome. Women initiate a faster and stronger natural and adaptive immune response, with early infections. Women can be protected from severity, but this same difference can make women more vulnerable to long-term autoimmune-related disorders. “

As part of the review, researchers will review the paper between December 2019 and August 2020 for COVID-19 and June 2021 for long-term COVID syndrome in January 2020. Limited to a limited time. They evaluated the possibility of including 4346 publications in their reviews. Twenty-three met the criteria for the study of COVID-19 sequelae and 12 met the criteria for long-term COVID syndrome. Assuming each participant in each article of a unique individual, the sample size is 1.39 million patients, and the largest study includes 1.32 million patients.

In the next category, women were more likely to have symptoms of COVID-19 than men.

• Psychiatry / Mood: (odds ratio) [OR]1.80; 95% CI, 1.35 to 2.41)
• Ears, nose, throat: (OR, 1.42; 95% CI, 1.39–1.46)

• Musculoskeletal system: (OR, 1.15; 95% CI, 1.14–1.16)
• Respiratory system: (OR, 1.09; 95% CI, 1.08–1.11)

However, women were less likely to have renal symptoms than men (OR = 0.83; 95% CI, 0.75–0.93).

Not only were women more likely to have longer COVIDs (OR, 1.22; 95% CI, 1.13–1.32), but overall findings were uniform for women-related symptoms. more pronunciation.

Longer COVIDs increase the likelihood that women will develop these symptoms in the long term.

1. Ears, nose, throat: (OR, 2.28; 95% CI, 1.94–2.67)
2. Gastrointestinal: (OR, 1.60; 95% CI, 1.04–2.44)
3. Psychiatry / Mood: (OR, 1.58; 95% CI, 1.37–1.82)
4. Neurological: (OR, 1.30; 95% CI, 1.03–1.63)
5. Dermatology: (OR, 1.29; 95% CI, 1.05–1.58)

Other less obvious symptoms remained more likely among women with long COVID (OR, 1.36; 95% CI, 1.25–1.49), but men with long COVID may have endocrine. Was high (OR, 0.75; 95% CI, 0.69–0.81) and renal impairment (OR, 0.74; 95% CI, 0.64–0.86).

The authors “emphasize the need for further gender studies / reporting of COVID-19 disease,” despite clear gender differences in both COVID and long-term COVID symptoms, most studies reporting gender data. I pointed out that there is no such thing.

“By devising basic research and clinical trial protocols using gender-specific methodologies, with the primary purpose of positively assessing aspects of COVID-19 by gender, we can bridge the critical information gap. “Masu,” the author writes. “A complete understanding of how biological gender affects COVID-19 is important for clinical management and mitigation strategies for this disease.”

“It has the potential to reshape the natural history of COVID-19,” they concluded.

reference

Sylvester SV, Rusu R, Chan B, Bellows M, O’Keefe C, Nicholson S. COVID-19 Gender Differences between Infection Sequelae and Long COVID Syndrome: Review. Curr Med Res Opin.. Published online June 20, 2022. doi: 10.1080 / 03007995.2022.2081454